Eledon Pharmaceuticals, Inc.
ELDN
$2.82
-$0.11-3.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 16.44% | -0.23% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 7.97% | -1.41% | |||
| Operating Income | -7.97% | 1.41% | |||
| Income Before Tax | 18.95% | -274.81% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 18.95% | -273.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 18.95% | -273.55% | |||
| EBIT | -7.97% | 1.41% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 19.81% | -218.75% | |||
| Normalized Basic EPS | 19.80% | -219.62% | |||
| EPS Diluted | 19.81% | -218.75% | |||
| Normalized Diluted EPS | 19.80% | -219.62% | |||
| Average Basic Shares Outstanding | 1.05% | 17.20% | |||
| Average Diluted Shares Outstanding | 1.05% | 17.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||